Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

36.24 +0.51 (+1.43%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
28 29 Next >
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial
Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape... 
Via Benzinga
Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen... 
Via Benzinga
Genentech’s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma
From Genentech
Via Business Wire
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that... 
Via Benzinga
Biotech Playbook 2021: No Help From Small Caps In Q4
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60%... 
Via Benzinga
Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
From Genentech
Via Business Wire
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
Exposures Product Safety
Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab
From Genentech
Via Business Wire
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial
Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS).... 
Via Benzinga
Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer
Roche Holdings AG (OTC: RHHBY) reported follow-up efficacy, safety, and patient-reported outcomes data from the Phase 2 CITYSCAPE trial of tiragolumab plus... 
Via Benzinga
New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq
From Genentech
Via Business Wire
Wednesday Global Investing Report
Between the Amazon Cloud issues and the clouds gathering over the Ukraine border, it's getting harder to tell exactly what's happening to markets. Here are some insights into the international... 
Via Talk Markets
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. 
Via InvestorPlace
Exposures COVID-19
Europe Approves Roche's Tocilizumab For Patients With Severe COVID-19
The European Commission has extended the marketing authorization for Roche Holdings AG's (OTC: RHHBY) Actemra/RoActemra (Tocilizumab) to treat patients with severe... 
Via Benzinga
recession in 2022?
China has cut its reserve requirement for lending by 50% giving a $188 bn boost to its market. 
Via Talk Markets
Topics Economy
Exposures Economy
How Did Healthcare Stocks Perform Over This Volatile Month?
It’s been a rough month for small-cap biotech stocks amidst a general correction in the market which brought general indices down about 10%. 
Via Talk Markets
Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients
Immunocore Holdings Plc (NASDAQ: IMCR) announced the initial Phase 1 data of IMC-C103C, a bispecific T cell engager targeting MAGE-A4, in selected advanced solid... 
Via Benzinga
Charms Of China
Today the global stock market rout was pretty awful. 
Via Talk Markets
Biden's New COVID-19 Plan Includes Reimbursement For Over The Counter, At-Home COVID Tests
President Biden announced that private health insurance plans would soon reimburse people who buy over-the-counter (OTC), at-home rapid tests for COVID-19. What Happened... 
Via Benzinga
Exposures COVID-19
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS) and Roche Holdings AG (OTC: RHHBY... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland... 
Via Benzinga
Exposures Product Safety
35 Stocks Moving In Tuesday's Mid-Day Session
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an... 
Via Benzinga
Exposures Product Safety
ImmunoGen Shares Rally After Ovarian Cancer Trial Meets Primary Endpoint Goal
ImmunoGen Inc (NASDAQ: IMGN) shares have gained more than 30% during premarket trading in reaction to positive topline data from the SORAYA trial of mirvetuximab... 
Via Benzinga
As FINRA's OTC Bulletin Board Closes Down, OTC Markets Group Becomes the Main Gateway Into the Regulated Over-the-Counter Market
Photo by Marga Santoso on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?
The Swiss pharma needs to get its drug approved first. 
Via The Motley Fool
Exposures Product Safety
How AI Is Reducing The Costly Toll Of Cancer Drug Development And Disrupting The BioPharma Space
Bio-pharmaceutical investors know full well the drug discovery and development can be a long and uncertain process. Nowhere is that more true than in cancer drugs. This review looks at the history and... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders
From Genentech
Via Business Wire
Detecting Early Cancer Screening Stocks At An Early Stage Is Critical
If you're going to get cancer, you’re going to want to detect it early. While we’ve come a long way, baby, when it comes to treating terrible maladies like lung... 
Via Benzinga
Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much
The therapy will likely face stiff competition from more convenient COVID-19 pills. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS